Twist Bioscience Co. (NASDAQ:TWST) Given Consensus Rating of “Moderate Buy” by Brokerages

Shares of Twist Bioscience Co. (NASDAQ:TWST) have received an average rating of “Moderate Buy” from the nine brokerages that are presently covering the firm, MarketBeat Ratings reports. One investment analyst has rated the stock with a sell recommendation, one has given a hold recommendation and seven have issued a buy recommendation on the company. The average 1 year price objective among analysts that have issued a report on the stock in the last year is $51.78.

Several research analysts recently commented on TWST shares. Evercore ISI increased their price objective on Twist Bioscience from $52.00 to $56.00 and gave the company an “outperform” rating in a research note on Tuesday, October 1st. Leerink Partners raised their price target on shares of Twist Bioscience from $45.00 to $48.00 and gave the stock a “market perform” rating in a research note on Thursday, October 17th. Robert W. Baird upped their price objective on shares of Twist Bioscience from $46.00 to $48.00 and gave the company an “outperform” rating in a research note on Tuesday, November 19th. Barclays decreased their target price on shares of Twist Bioscience from $55.00 to $52.00 and set an “overweight” rating on the stock in a research note on Tuesday, November 19th. Finally, JPMorgan Chase & Co. upped their price target on Twist Bioscience from $28.00 to $35.00 and gave the company an “underweight” rating in a research report on Monday, August 5th.

Insider Activity

In related news, CEO Emily M. Leproust sold 1,730 shares of the firm’s stock in a transaction dated Friday, September 20th. The stock was sold at an average price of $46.94, for a total transaction of $81,206.20. Following the completion of the sale, the chief executive officer now directly owns 495,523 shares of the company’s stock, valued at approximately $23,259,849.62. This trade represents a 0.35 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, CAO Robert F. Werner sold 1,448 shares of the company’s stock in a transaction dated Wednesday, November 6th. The shares were sold at an average price of $44.60, for a total transaction of $64,580.80. Following the completion of the transaction, the chief accounting officer now directly owns 45,620 shares in the company, valued at $2,034,652. The trade was a 3.08 % decrease in their position. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 98,118 shares of company stock valued at $4,391,151. 3.92% of the stock is currently owned by company insiders.

Institutional Investors Weigh In On Twist Bioscience

A number of institutional investors and hedge funds have recently made changes to their positions in TWST. State Street Corp boosted its position in shares of Twist Bioscience by 19.9% during the 3rd quarter. State Street Corp now owns 3,167,353 shares of the company’s stock worth $143,101,000 after purchasing an additional 526,028 shares during the period. Geode Capital Management LLC boosted its position in shares of Twist Bioscience by 1.9% during the third quarter. Geode Capital Management LLC now owns 1,367,759 shares of the company’s stock worth $61,807,000 after buying an additional 26,145 shares during the period. Thrivent Financial for Lutherans acquired a new stake in shares of Twist Bioscience in the third quarter valued at $43,992,000. Wellington Management Group LLP raised its holdings in shares of Twist Bioscience by 188.5% in the 3rd quarter. Wellington Management Group LLP now owns 797,737 shares of the company’s stock valued at $36,042,000 after buying an additional 521,272 shares during the period. Finally, Fred Alger Management LLC lifted its stake in Twist Bioscience by 17.1% during the 3rd quarter. Fred Alger Management LLC now owns 767,149 shares of the company’s stock worth $34,660,000 after acquiring an additional 112,272 shares in the last quarter.

Twist Bioscience Trading Up 9.9 %

NASDAQ:TWST opened at $46.40 on Tuesday. The stock has a 50 day moving average of $43.78 and a two-hundred day moving average of $46.15. Twist Bioscience has a 12 month low of $23.07 and a 12 month high of $60.90. The firm has a market cap of $2.75 billion, a P/E ratio of -12.89 and a beta of 1.78.

Twist Bioscience Company Profile

Twist Bioscience Corporation engages in the manufacture and sale of synthetic DNA-based products. The company offers synthetic genes and gene fragments used in product development for therapeutics, diagnostics, chemicals/materials, food/agriculture, data storage, and various applications within academic research by biotech, pharma, industrial chemical, and agricultural companies, as well as academic labs; Oligo pools used in targeted NGS, CRISPR gene editing, mutagenesis experiments, DNA origami, DNA computing, data storage in DNA, and other applications; and immunoglobulin G proteins for customers focused on the pursuit of drug discovery and development.